ECDB-Endometrial cancer gene database

REFERENCES

Gene Name	Gene ID	Pubmed ID	Classification	Mechanism	Marker	Type	Normal Cases	Disease Cases	Age	Mean Age	Place	FIGO	Grade	Remark	Title	Journal	Volume	Year
TNFRSF10C	8794	19936781	-	Up regulation/ Over expression/High expression	-	-	80	62	49 to 88	68.4	Hospital Univesritari Arnau de Vilanova de Lleida and Hospital de Sant Pau; Barcelona; Spain	-	1 (n=22); 2 (n=24); 3 (n=7); 3 mixed endometroid and non-endometroid; 2 non-endometroid carcinoma grade 3; and the epithelial componenets of four malignant mixed Mullerian tumors.	[1] By Immunohistochemical; cytoplasmic expression of DcR1 was frequently seen in NE (79.6%) and varied according to the menstrual cycle. Positive DcR1 immunostaining was also detected in EC (98.1% of the cases) without any specific statistical association with histological type; grade; and stage. By quantitative real-time PCR; all NE had similar levels of DcR1expression (0.8-1.7 RQ); which were considered the basal levels of DcR1 expression in NE. [2] Increased DcR1 expression (> or =5-fold higher than the basal levels) was detected in 13 of 28 EC (46.4%). [3] High DcR1 expression levels were found in ECs of different stages: IA; four of 12 (33%); IB; two of four (50%); IC; four of six (66%); and IIA and IIB three of six (50%). Results suggest that DcR1 expression occurs in a subset of EC and may contribute to resistance to TRAIL-induced apoptosis.	DcR1 expression in endometrial carcinomas	Virchows Archiv	456(1):39-44	2010